GW Pharmaceuticals plc
E_DEPRECATED Error in file »functions_general.php« at line 326: Function utf8_encode() is deprecated
E_DEPRECATED Error in file »functions_general.php« at line 326: Function utf8_encode() is deprecated
E_DEPRECATED Error in file »functions_general.php« at line 186: Function utf8_encode() is deprecated
E_DEPRECATED Error in file »functions_general.php« at line 186: Function utf8_encode() is deprecated
Category
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy.
Keywords: